in this 9-month, real-life, prospective, non-interventional, longitudinal, multicenter study of patients with primary and secondary immunodeficiencies in france, treatment modalities , efficacy, safety, tolerability, quality of life, and treatment satisfaction were evaluated using descriptive statistics.
although hizentra is indicated for immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies, phase iii trials have focused on patients with primary immunodeficiencies.
secondary immunodeficiencies were present in  <dig>  % of patients.
under real-life conditions and in a cohort that included patients with primary and secondary immunodeficiencies, treatment with hizentra was effective and well tolerated and patients were generally satisfied with the treatment.
the median dose of hizentra administered was  <dig>  g/kg/injection.
scores on the treatment satisfaction questionnaire for medication ranged from  <dig>  ±  <dig>  to  <dig>  ±  <dig>  depending on the domain.
no single drug-related systemic reaction occurred in more than one patient and few local reactions were reported .
